Company profile

Bausch Health Companies Inc.

Pipeline2 assets

LarsucosterolDUR-928 / Epigenetic modulator / Hepatology
Alcohol-associated hepatitisPhase 3Registrational Phase 3 initiated in early 2026US
AmiselimodMT-1303 / S1P receptor / Oral S1P modulator / Gastroenterology
Mild-to-moderate ulcerative colitisPhase 2Internal review of opportunity ongoing

Latest news15 items

May 28, 2026

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

May 19, 2026

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

May 13, 2026

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

May 12, 2026

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Apr 29, 2026

Bausch Health Announces First Quarter 2026 Results

Apr 14, 2026

Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

Mar 31, 2026

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

Mar 26, 2026

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

Feb 23, 2026

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant MD Touch Laser in Canada (French)

Feb 23, 2026

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

Feb 19, 2026

Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

Feb 18, 2026

Bausch Health Announces Fourth Quarter and Full-Year 2025 Results

Feb 17, 2026

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

Feb 11, 2026

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program

Jan 23, 2026

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Bausch Health Companies Inc. • Endpoint Arena